<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615403</url>
  </required_header>
  <id_info>
    <org_study_id>IDOS-106-EXCH</org_study_id>
    <nct_id>NCT04615403</nct_id>
  </id_info>
  <brief_title>Study of Exchange of Travoprost Intraocular Implant</brief_title>
  <official_title>Prospective, Non-Randomized, Open-Label, Multi-Center, Single Arm Study of Exchange of Travoprost Intraocular Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to evaluate the safety of the operative and surgical exchange&#xD;
      procedure of Travoprost Intraocular Implant in subjects with open-angle glaucoma or ocular&#xD;
      hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, non-randomized, open-label, multi-center, single arm, clinical trial&#xD;
      intends to implant approximately 45 male and female subjects over 18 years old who have been&#xD;
      diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT). All subjects are&#xD;
      required to meet eligibility criteria at Visit 1 (Screening). The purpose of this study is to&#xD;
      evaluate the safety of the implantation and exchange of a Travoprost Intraocular Implant in&#xD;
      subjects with open-angle glaucoma or ocular hypertension. Postoperatively, there are 6&#xD;
      follow-up visits over a 12 month period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Safety Measures</measure>
    <time_frame>12 Months</time_frame>
    <description>Adverse Events including intr-operative and post-operative events (TEAE's)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>12 Months</time_frame>
    <description>Intraocular Pressure (IOP) in millimeters of Mercury (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>12 Months</time_frame>
    <description>Corrected Visual Acuity measured from ETDRS Visual Acuity Chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Edema</measure>
    <time_frame>12 Months</time_frame>
    <description>Slit Lamp Biomicroscopy Findings of the eye and adnexa. Findings to be assessed include:&#xD;
Corneal Edema (Scale: none, mild, moderate, or severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Opacity</measure>
    <time_frame>12 Months</time_frame>
    <description>Slit Lamp Biomicroscopy Findings of the eye and adnexa. Findings to be assessed include:&#xD;
Corneal Opacity (Scale: none, mild, moderate, or severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Epithelium</measure>
    <time_frame>12 Months</time_frame>
    <description>Slit Lamp Biomicroscopy Findings of the eye and adnexa. Findings to be assessed include:&#xD;
Corneal Epithelium (Normal, or Punctate staining presence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Endothlium</measure>
    <time_frame>12 Months</time_frame>
    <description>Slit Lamp Biomicroscopy Findings of the eye and adnexa. Findings to be assessed include:&#xD;
Corneal Endothelium (Scale: Normal, 1 fold, 2 folds, 3 folds, 4 folds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior Chamber Cells</measure>
    <time_frame>12 Months</time_frame>
    <description>Slit Lamp Biomicroscopy Findings of the eye and adnexa. Findings to be assessed include:&#xD;
Anterior Chamber Cells (Scale: &lt;1 cells, 1-5 cells, 6-15 cells, 16-25 cells, 26-50 cells, or &gt;50 cells)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior Chamber Flare</measure>
    <time_frame>12 Months</time_frame>
    <description>Slit Lamp Biomicroscopy Findings of the eye and adnexa. Findings to be assessed include:&#xD;
Anterior Chamber Flare (Scale: None, Faint, Moderate, Marked, Intense)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iris - Neovascularization</measure>
    <time_frame>12 Months</time_frame>
    <description>Slit Lamp Biomicroscopy Findings of the eye and adnexa. Findings to be assessed include:&#xD;
Iris - Neovascularization (No, or Yes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iris - Atrophy</measure>
    <time_frame>12 Months</time_frame>
    <description>Slit Lamp Biomicroscopy Findings of the eye and adnexa. Findings to be assessed include:&#xD;
Iris - Atrophy (No, or Yes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iris - Pigment Dispersion</measure>
    <time_frame>12 Months</time_frame>
    <description>Slit Lamp Biomicroscopy Findings of the eye and adnexa. Findings to be assessed include:&#xD;
Iris - Pigment Dispersion (No, or Yes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupil</measure>
    <time_frame>12 Months</time_frame>
    <description>Slit Lamp Biomicroscopy Findings of the eye and adnexa. Findings to be assessed include:&#xD;
Pupil (normal, abnormal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lens Status</measure>
    <time_frame>12 Months</time_frame>
    <description>Slit Lamp Biomicroscopy Findings of the eye and adnexa. Findings to be assessed include:&#xD;
Lens Status - phakic/psedophakic; if opacity present grading (Opacity location and severity) graded using the Age-Related Eye Disease Study (AREDS) Clinical Lens Grading System (ARLNS) Implant Assessment - (Location, Iris Touch, Endothelial Touch)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gonioscopy</measure>
    <time_frame>12 Months</time_frame>
    <description>Gonioscopy findings of the anterior chamber and angle of the eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specular Microscopy</measure>
    <time_frame>12 Months</time_frame>
    <description>Specular Microscopy Findings of corneal endothelium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dilated Fundus Examination</measure>
    <time_frame>12 Months</time_frame>
    <description>Dilated Fundus examination performed via ophthalmoscopy including cup-to-disc ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Field</measure>
    <time_frame>12 Months</time_frame>
    <description>Visual Field changes in Mean Deviation over time (MD of visual field loss)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Implantation and Exchange</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo implantation and exchange of a Travoprost Intraocular Implant through a small temporal clear corneal incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost</intervention_name>
    <description>Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision</description>
    <arm_group_label>Implantation and Exchange</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to attend scheduled follow-up exams for the duration of the study&#xD;
&#xD;
          -  Able and willing to provide written informed consent on the IRB (institutional review&#xD;
             board)/IEC (institutional ethics committee)-approved Informed Consent form&#xD;
&#xD;
          -  Best spectacle corrected visual acuity of 20/80 or better in each eye.&#xD;
&#xD;
          -  Previously qualified for GC-009 clinical trial using the Travoprost Intraocular&#xD;
             Implant with the travoprost intraocular implant (G2TR) that is present in the study&#xD;
             eye.&#xD;
&#xD;
          -  Angle anatomy defined as follows:&#xD;
&#xD;
               -  Open angle as defined by Shaffer grade â‰¥ 3 at slit-lamp at the planned&#xD;
                  implantation site&#xD;
&#xD;
               -  Normal anatomy as determined by gonioscopy&#xD;
&#xD;
               -  Absence of peripheral anterior synechia (PAS), rubeosis or other angle&#xD;
                  abnormalities that could impair proper placement of the product at the planned&#xD;
                  implantation site&#xD;
&#xD;
          -  Able to provide an adequate and interpretable visual field examination result&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Glaucoma status as follows:&#xD;
&#xD;
               -  Traumatic, uveitic, neovascular, or angle-closure glaucoma; or glaucoma&#xD;
                  associated with vascular disorders&#xD;
&#xD;
               -  Functionally significant visual field loss, including severe nerve fiber bundle&#xD;
                  defects&#xD;
&#xD;
               -  Prior incisional glaucoma surgery (original iDose implantation procedure allowed)&#xD;
&#xD;
               -  History of laser iridotomy or laser trabeculoplasty within the last 90 days&#xD;
&#xD;
          -  Corneal status as follows:&#xD;
&#xD;
               -  Any active inflammation or edema (e.g. keratitis, keratoconjunctivitis,&#xD;
                  keratouveitis)&#xD;
&#xD;
               -  Clinically significant dystrophy (e.g. bullous keratopathy, Fuch's dystrophy)&#xD;
&#xD;
               -  Clinically significant guttata&#xD;
&#xD;
               -  Significant scarring or irregularities (including scars from prior corneal&#xD;
                  surgery such as PKP (penetrating Keratoplasty), RK (radial keratotomy), etc.),&#xD;
                  during the course of the study, that may interfere with IOP measurement&#xD;
                  reliability&#xD;
&#xD;
               -  Opacities or disorders that would inhibit visualization of the nasal angle&#xD;
&#xD;
          -  Congenital or traumatic cataract (except Mittendorf dots)&#xD;
&#xD;
          -  Coroidal detachment, effusion, choroiditis, neovascularization, or any active&#xD;
             choroidopathy.&#xD;
&#xD;
          -  Retinal or optic nerve disorders, either degenerative or evolutive, that are not&#xD;
             associated with the existing glaucoma condition, including proliferative diabetic&#xD;
             retinopathy (mild background diabetic retinopathy permissible), central retinal artery&#xD;
             occlusion, (e.g. presence of numerous large drusen associated with disturbance to or&#xD;
             elevation of the retinal pigment epithelium), significant retinal pigment epithelial&#xD;
             changes or optic atrophy.&#xD;
&#xD;
          -  Other ocular status as follows:&#xD;
&#xD;
               -  Clinically significant sequelae from trauma (e.g. chemical burns, blunt trauma,&#xD;
                  etc.)&#xD;
&#xD;
               -  History of chronic ocular inflammatory disease or presence of active ocular&#xD;
                  inflammation (e.g. uveitis, iritis, iridocyclitis, retinitis, ocular herpes)&#xD;
&#xD;
               -  Any pathology for which, in the investigator's judgement, the following would be&#xD;
                  either at risk or contraindicated:&#xD;
&#xD;
          -  Implantation of Travoprost Intraocular Implant&#xD;
&#xD;
          -  Compliance to elements of the study protocol (e.g., ophthalmic examinations, follow-up&#xD;
             visits)&#xD;
&#xD;
          -  Fellow eye status as follows:&#xD;
&#xD;
               -  Fellow eye actively enrolled in this trial or any other clinical trial&#xD;
&#xD;
          -  Subject status as follows:&#xD;
&#xD;
               -  Pregnant or planning to become pregnant during the course of the study&#xD;
&#xD;
               -  Uncontrolled systemic disease (e.g., diabetes, hypertension) that could&#xD;
                  compromise their participation in the study&#xD;
&#xD;
               -  Current participation in any study or participation within 30 calendar days of&#xD;
                  Visit 1 (screening)&#xD;
&#xD;
               -  Immunodeficiency conditions&#xD;
&#xD;
               -  Change in an existing chronic systemic therapy that could substantially affect&#xD;
                  IOP or the study outcomes within 30 days prior to Visit 1 (screening), or&#xD;
                  anticipated change in such therapy during the study duration&#xD;
&#xD;
               -  Known allergy, hypersensitivity or contraindication to the study medications or&#xD;
                  their components, namely prostaglandin analogues&#xD;
&#xD;
               -  Any ocular disease or condition that in the opinion of the investigator or&#xD;
                  Medical Monitor may put the subject at significant risk, may confound the study&#xD;
                  results, or may interfere significantly with the subject's participation in the&#xD;
                  study. In addition, the investigator or the Medical Monitor may declare any&#xD;
                  subject ineligible for any sound medical reason&#xD;
&#xD;
          -  The inability to visualize the implantation site via surgical gonioscopy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inland Eye Specialists</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bath Eye Associates, Inc.</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Center of northern Colorado, PC</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Associates of Manatee</name>
      <address>
        <city>Manatee</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Eye</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Sight</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jones Eye Clinic</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>D'Ambrosio Eye Care</name>
      <address>
        <city>Lancaster</city>
        <state>Massachusetts</state>
        <zip>01523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern New Jersey Eye Institute</name>
      <address>
        <city>South Orange</city>
        <state>New Jersey</state>
        <zip>07079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Eye Surgeons</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texan Eye</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehmann Eye Center</name>
      <address>
        <city>Nacogdoches</city>
        <state>Texas</state>
        <zip>75965</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asian Eye Institute</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

